Chemomab Therapeutics

Chemomab Therapeutics is a distinguished pharmaceutical manufacturing company dedicated to developing innovative therapeutics for diseases at the confluence of fibrosis and inflammation, addressing areas with high unmet needs. Chemomab Therapeutics is committed to pioneering solutions in the biotechnology sector, specifically targeting fibro-inflammatory diseases. Based on the critical role of the chemokine CCL24, Chemomab has developed CM-101, a monoclonal antibody engineered to neutralize CCL24 activity.

Located in Tel Aviv at Kiryat Atidim, Building 7, 6158002, IL, Chemomab Therapeutics focuses on creating safe and well-tolerated treatments with the potential to address multiple severe and life-threatening conditions. Encouraging results have been reported from Phase 2 biomarker studies in NASH patients, as well as investigator studies involving patients with severe lung injury. Currently, Chemomab Therapeutics is conducting a Phase 2 trial involving patients with primary sclerosing cholangitis.

Chemomab Therapeutics continues to advance its research and development efforts, striving to improve patient outcomes and quality of life through cutting-edge pharmaceutical innovations. We invite the management team at Chemomab Therapeutics to enhance your company's visibility by creating a customized and exclusive company showcase and product listing on our platform, further highlighting your contributions to the pharmaceutical industry.